96 related articles for article (PubMed ID: 20523161)
1. Association of Asn221Ser mutation in tissue factor pathway inhibitor-beta with plasma total tissue factor pathway inhibitor level.
Ishikawa J; Okada H; Kato H; Takeshita S; Honda S; Kawasaki T; Suehisa E; Tsuji H; Madoiwa S; Sakata Y; Kojima T; Murata M; Ikeda Y; Kokubo Y; Okamura T; Tomoike H; Miyata T
Blood Coagul Fibrinolysis; 2009 Jan; 20(1):22-6. PubMed ID: 20523161
[TBL] [Abstract][Full Text] [Related]
2. Analysis of a T-287C polymorphism in the tissue factor pathway inhibitor gene and identification of a repressor element in the promoter.
Amini Nekoo A; Iles D
Thromb Res; 2008; 121(6):813-9. PubMed ID: 17931693
[TBL] [Abstract][Full Text] [Related]
3. Tissue factor pathway inhibitor polymorphisms in women with and without a history of venous thrombosis and the effects of postmenopausal hormone therapy.
Opstad TB; Eilertsen AL; Høibraaten E; Skretting G; Sandset PM
Blood Coagul Fibrinolysis; 2010 Sep; 21(6):516-21. PubMed ID: 20453636
[TBL] [Abstract][Full Text] [Related]
4. Haplotype of thrombomodulin gene associated with plasma thrombomodulin level and deep vein thrombosis in the Japanese population.
Sugiyama S; Hirota H; Kimura R; Kokubo Y; Kawasaki T; Suehisa E; Okayama A; Tomoike H; Hayashi T; Nishigami K; Kawase I; Miyata T
Thromb Res; 2007; 119(1):35-43. PubMed ID: 16507317
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms of the tissue factor pathway inhibitor gene are associated with venous thromboembolism in the antiphospholipid syndrome and carriers of factor V Leiden.
Lincz LF; Adams MJ; Scorgie FE; Thom J; Baker RI; Seldon M
Blood Coagul Fibrinolysis; 2007 Sep; 18(6):559-64. PubMed ID: 17762532
[TBL] [Abstract][Full Text] [Related]
6. Tissue factor pathway inhibitor anticoagulant activity: risk for venous thrombosis and effect of hormonal state.
Dahm A; Rosendaal FR; Andersen TO; Sandset PM
Br J Haematol; 2006 Feb; 132(3):333-8. PubMed ID: 16409298
[TBL] [Abstract][Full Text] [Related]
7. The 536C-->T transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis.
Kleesiek K; Schmidt M; Götting C; Schwenz B; Lange S; Müller-Berghaus G; Brinkmann T; Prohaska W
Thromb Haemost; 1999 Jul; 82(1):1-5. PubMed ID: 10456444
[TBL] [Abstract][Full Text] [Related]
8. Tissue factor pathway inhibitor relates to fibrin degradation in patients with acute deep venous thrombosis.
Sidelmann JJ; Bladbjerg EM; Gram J; Münster AM; Jespersen J
Blood Coagul Fibrinolysis; 2008 Jul; 19(5):405-9. PubMed ID: 18600090
[TBL] [Abstract][Full Text] [Related]
9. The -33T-->C polymorphism in intron 7 of the TFPI gene influences the risk of venous thromboembolism, independently of the factor V Leiden and prothrombin mutations.
Ameziane N; Seguin C; Borgel D; Fumeron F; Moatti D; Alhenc-Gelas M; Grandchamp B; Aiach M; Emmerich J; de Prost D
Thromb Haemost; 2002 Aug; 88(2):195-9. PubMed ID: 12195688
[TBL] [Abstract][Full Text] [Related]
10. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis.
Ariëns RA; Alberio G; Moia M; Mannucci PM
Thromb Haemost; 1999 Feb; 81(2):203-7. PubMed ID: 10063992
[TBL] [Abstract][Full Text] [Related]
11. Association of genetic polymorphisms with plasma TFPI level: Boon or curse for DVT patients - Study from India.
Kamal K; Amit S; Kanwaljeet S; Ravi R; Hareram P; Ravi K; Kumar KV; Pravas M; Renu S
Blood Cells Mol Dis; 2017 Jul; 66():31-36. PubMed ID: 28810169
[TBL] [Abstract][Full Text] [Related]
12. Functional characterization of polymorphisms in the human TFPI gene.
Skretting G; Stavik B; Landvik NE; Myklebust CF; Iversen N; Zienolddiny S; Sandset PM
Biochem Biophys Res Commun; 2010 Jun; 397(1):106-11. PubMed ID: 20519147
[TBL] [Abstract][Full Text] [Related]
13. Anticoagulant versus amidolytic activity of tissue factor pathway inhibitor in coronary artery disease.
Mukherjee M; Ranlall N; Patel G; Rutlin A; Jehanli A; Kakkar VV
Blood Coagul Fibrinolysis; 2000 Apr; 11(3):285-91. PubMed ID: 10870809
[TBL] [Abstract][Full Text] [Related]
14. Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: preliminary study.
Gosk-Bierska I; Wysokin Ski W; Karnicki K; Adamiec R
Int Angiol; 2008 Aug; 27(4):296-301. PubMed ID: 18677291
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis.
Amini-Nekoo A; Futers TS; Moia M; Mannucci PM; Grant PJ; Ariëns RA
Br J Haematol; 2001 May; 113(2):537-43. PubMed ID: 11380428
[TBL] [Abstract][Full Text] [Related]
16. A locus on chromosome 2 influences levels of tissue factor pathway inhibitor: results from the GAIT study.
Almasy L; Soria JM; Souto JC; Warren DM; Buil A; Borrell M; Muñoz X; Sala N; Lathrop M; Fontcuberta J; Blangero J
Arterioscler Thromb Vasc Biol; 2005 Jul; 25(7):1489-92. PubMed ID: 15845911
[TBL] [Abstract][Full Text] [Related]
17. Tissue factor pathway inhibitor (TFPI) levels in the plasma and urine of children with meningococcal disease.
Eling M; Stephens AC; Oragui EE; Rivers RP; Levin M
Thromb Haemost; 2001 Feb; 85(2):240-4. PubMed ID: 11246540
[TBL] [Abstract][Full Text] [Related]
18. Influence of Amerindian mitochondrial DNA haplogroups on thrombosis susceptibility and frequency of four genetic prothrombotic variants in Southern Chilean subjects.
Guzmán N; Lanas F; Salazar LA
Clin Chim Acta; 2010 Mar; 411(5-6):444-7. PubMed ID: 20064497
[TBL] [Abstract][Full Text] [Related]
19. Differences in circadian variations of tissue factor pathway inhibitor type 1 between able-bodied and spinal cord injured.
Dahm AE; Iversen PO; Hjeltnes N; Sandset PM
Thromb Res; 2006; 118(2):281-7. PubMed ID: 16139333
[TBL] [Abstract][Full Text] [Related]
20. Plasma free tissue factor pathway inhibitor (TFPI) levels and TF-induced thrombin generation ex vivo in men with low testosterone levels.
Agledahl I; Brodin E; Svartberg J; Hansen JB
Thromb Haemost; 2009 Mar; 101(3):471-7. PubMed ID: 19277407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
